Structure of Tolinapant
CAS No.: 1799328-86-1
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
An orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptotic activities.
Synonyms: ASTX660
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1799328-86-1 |
Formula : | C30H42FN5O3 |
M.W : | 539.68 |
SMILES Code : | C[C@H]1N(C[C@@H]2N(CC(N3CC(C)(C)C4=NC(CO)=C(CC5=CC=C(F)C=C5)C=C43)=O)C[C@@H](C)NC2)CCOC1 |
Synonyms : |
ASTX660
|
MDL No. : | MFCD31619274 |
InChI Key : | YCXOHEXZVKOGEV-DNRQZRRGSA-N |
Pubchem ID : | 118169620 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
A549 (Human) | 0.014-10 μM | 48-80 hours | To evaluate the immune-mediated killing effects of Tolinapant on A549 cells. Results showed that Tolinapant significantly increased apoptosis of A549 cells in the presence of activated PBMCs. | PMC8945623 |
HH (Human) | 0.001-10 μM | 72 hours | To evaluate the cytotoxic effects of Tolinapant on the human TCL cell line HH. Results showed that Tolinapant had minimal impact on HH cell viability within 72 hours, but the effect was enhanced in the presence of TNF-α. | PMC8945623 |
BW5147.G.1.4 (Mouse) | 0.001-10 μM | 72 hours | To evaluate the cytotoxic effects of Tolinapant on the mouse TCL cell line BW5147.G.1.4. Results showed that Tolinapant significantly reduced cell viability within 72 hours, especially in the presence of TNF-α. | PMC8945623 |
MDA-MB-231 cells | 4.4 nM (GI50) | Evaluate the inhibitory effect of Tolinapant on MDA-MB-231 cells | PMC11503241 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | BW5147 syngeneic model | Oral | 25 mg/kg | Once daily for 15 days | To evaluate the antitumor effects of Tolinapant in the BW5147 syngeneic model. Results showed that Tolinapant treatment led to complete tumor regression, and no tumor recurrence was observed within 30 days after treatment cessation. | PMC8945623 |
Mice | MDA-MB-231 xenograft models | Oral | 30 mg/kg | Once daily | Evaluate the efficacy of Tolinapant in MDA-MB-231 xenograft models | PMC11503241 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02503423 | Solid Tumors|Lymphoma | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2025-12-25 | University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35294, United States|HonorHealth Research Institute, Scottsdale, Arizona, 852558, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|UC Davis Medical Center, Sacramento, California, 95817, United States|Simlow Cancer Hospital at Yale, New Haven, Connecticut, 06510, United States|Emory University winship Cancer Institute, Atlanta, Georgia, 30322, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, 60611, United States|The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, 21287, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Dartmouth-Hitchcock Medical Center (DHMC), Lebanon, New Hampshire, 03766, United States|Summit Medical Group - Florham Park Campus/Atlantic Health, Florham Park, New Jersey, 07932, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|New York University Langone Medical Center, New York, New York, 10016, United States|New York Presbyterian Hospital Columbia University Medical Center, New York, New York, 10019, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Rochester Skin Lymphoma Medical Group, Rochester, New York, 14450, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|The Ohio State University and Wexner Medical Center, James Cancer Hospital, Columbus, Ohio, 43210, United States|University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|West Penn Hospital, Pittsburgh, Pennsylvania, 15224, United States|Hollings Cancer Center, Charleston, South Carolina, 29425, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37212, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|CliniCore Texas, Houston, Texas, 77079, United States|START- South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States|Virgina Commonwealth University, Richmond, Virginia, 23298, United States|University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne, Yvoir, Namur, B-5530, Belgium|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, 9000, Belgium|Intitut Jules Boredt, Bruxelles, 1000, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Nova Scotia Health Athority-Qeii HSC, Halifax, Nova Scotia, B3H 2Y9, Canada|Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M56 2M9, Canada|Jewish General Hospital, Montréal, Quebec, H3T 1E2, Canada|Gustave Roussy Cancer Campus (IGR), Villejuif, Cedex, 94805, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, Lyon, 69310, France|Institut Bergonié, Unicancer, Bordeaux, 33000, France|Centre Antoine Lacassagne, Oncologie Médicale, Nice, 06189, France|Centre Henri Becquerel, Hematology, Rouen, 1,76-38, France|Institut Universitaire du Cancer - Oncop?le, Department d'Hématologie, Toulouse Cedex 9, 31059, France|CRU de Tours - H?pital Bretonneau, Hématologie -Thérapy Cellulaire, Tours, 37044, France|Semmelweis Egyetem - I. sz. Belgyógyászati Klinika, Budapest, 1083, Hungary|Debreceni Egyetem Klinikai K?zpont, Debrecen, 4032, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Nyíregyháza, Hungary|Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi, Bologna, 40138, Italy|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, 25123, Italy|Instituto Europeo di Oncologia, Milan, Italy|Azienda Socio Santaria Territoriale Monza- Osperdale San Gerado, Monza, Italy|Institut Catala d'Oncologia, Girona, Giona, Spain|imCORE - Clínica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitario Fundacion Jimenez Diaz Preview, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|University Hospitals of Leicester NHS Trust, Leicester, East Midlands, LE1 5WW, United Kingdom|University Hospital Southhampton NHS Foundation Trust - Somers Cancer Research, Southampton, Hampshire, SO16 6YD, United Kingdom|Churchill Hospital, Oxford University Hospital NHS Trust, Oxford, Oxfordshire, OX3 7LE, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom|Beatson Cancer Center and University of Glasgow, Glasgow, G12 0XL, United Kingdom|University College London Hospitals NHS Foundation Trust, London, NW1 2PG, United Kingdom|Guy's and Saint Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom|The Christie NHS Foundation Trust, Christie Hospital, Manchester, M20 4BX, United Kingdom Less << |
NCT04479800 | Healthy Volunteer | PHASE1 | COMPLETED | 2020-08-25 | Worldwide Clinical Trials, San... More >> Antonio, Texas, 78217, United States Less << |
Tags: Tolinapant | ASTX660 | ASTX 660 | ASTX-660 | IAP | Apoptosis | cIAP inhibitor | XIAP antagonist | cIAP antagonist | apoptosis | cellular inhibitors of apoptosis protein | X-linked inhibitor of apoptosis protein | programmed cell death | 1799328-86-1
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL